Martin McMahon

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

The paper identifies a novel interaction between BRAFV600E and TP53 in melanoma, suggesting that BRAFV600E inactivates TP53, explaining the rarity of TP53 alterations in this cancer type.

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

This study shows that combining ULK1/2 inhibition with KRASG12C inhibitors reduces lung cancer growth in preclinical models.